Fundamental Data for MYL

MYLAN INC(NSDQ:MYL)

Mylan Laboratories Inc. and its subsidiaries are engaged in developing, licensing, manufacturing, marketing and distributing generic and branded pharmaceutical products. The company conducts business through its generic and branded pharmaceutical operating segments. The company is recognized as a leader in the generic pharmaceutical industry. The company attained its leadership position in the generic industrythrough its ability to obtain ANDA approvals, uncompromising quality control and devotion to customer service

# Employees: 15000

Address: 1500 Corporate Drive,Canonsburg,PA,USA

Phone: 724 514-1800

Fax:

Website: www.mylan.com

Email: investor_relations@mylan.com

Sector: Medical

Industry: MED-GENERIC DRG

Executive Officers

Milan Puskar (Chmn.; Dir.)

Robert J. Coury (Vice-Chmn.; C.E.O.; Dir.)

Daniel C. Rizzo Jr. (V.P.; Corporate Contrl.)

Edward J. Borkowski (C.F.O.)

Wendy Cameron (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/18/2010

Mean EPS (Next Qtr): $0.29

Mean EPS (Year): $1.26

Mean Estimate(Long Term): $17.75

P/E Ratio(Based on EPS estimate): 14.280

Number of Estimates: 15

Shares Performance

Period	MYL	Compare to S&P
YTD	82.10 %	50.70 %
4 Weeks	10.90 %	5.28 %
12 Weeks	23.95 %	15.42 %

Shares Information

Analyst Coverage: Y

Avg Volume: 5735094

Shares Outstanding: 305M

Market Cap: $5.50B

52 Week High: $18.30

52 Week Low: $8.85

P/E Ratio: 16.080

PEG Ratio: 0.800

Split: On 10/9/2003 MYL split by factor of 1.500

Earnings Performance

EPS Growth in Last Quarter: 0.00 %

EPS Growth in Last Year: 39.13 %

Sales Growth in Last Quarter: -0.23 %

Sales Growth in Last Quarter: -23.71 %

Financials

Qtr Book Value: $1.79

Cash Flow/Share: $6.79

Change in Payout Ratio: -0.130

Price/Sales: 1.110